Embecta Corp.
EMBCHealthcareNASDAQMedical Instruments & Supplies
Scan Results
Daily timeframeEmbecta Corp., a medical device company, provides solutions to improve the health and wellbeing of people living with diabetes in the United States and internationally. Valued at $380.2M, EMBC is a small-cap name in its sector. The company's products include pen needles, syringes, and safety injection devices, as well as digital applications to assist people with managing patient's diabetes.
Market Cap
$380.2M
Beta
0.83
P/E (TTM)
4.56
P/E (Fwd)
3.81
EPS (TTM)
$1.47
EPS (Fwd)
$1.76
ROE
—
ROA
12.2%
Cash
$214.7M
Total Debt
$1.50B
Free CF
$138.2M
52W Change
-53.2%
Annual Financials
Cash vs Debt
Where EMBC stands vs its 150-day and 200-day moving averages
As of the October 16, 2026 close, EMBC finished 20.11% above its 150-day moving average ($5.37) and 3.73% below its 200-day moving average ($6.70). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is EMBC overbought or oversold?
At the October 16, 2026 close, EMBC's RSI(14) was 64.2, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, EMBC has $214.7M in cash with $1.50B in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $138.2M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. Return on assets of 12.2% further supports the picture of efficient asset utilization. Revenue has been relatively flat, moving from $1.13B (2022) to $1.08B (2025).
The debt-to-cash ratio suggests meaningful leverage on the balance sheet, a factor worth monitoring if credit conditions tighten. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for Embecta Corp. and its sector.